Becton Dickinson & Co

BDX expands its BD MAX™ diagnostics with new IVDR‑cleared VIASURE assays, boosting EU market penetration and cost efficiency while investors weigh pricing and regulatory risks.

BD’s new insider sale, ChemoGLO partnership, and modular cell‑analyzer rollout boost safety, precision, and scalability in diagnostics.

BD’s CE‑approved Surgiphor cartridge is the first ready‑to‑use wound‑irrigation device in Europe, cutting OR prep time and lowering infection risk while opening new revenue and digital‑integration opportunities for hospitals.

Becton Dickinson & Co.’s recent strategic moves, including a partnership for early cancer detection and the milestone of 1,000th BD Rhapsody system, present both opportunities and risks, with the company’s robust cash flow and strong asset base prov…

Becton Dickinson & Co’s stock price is experiencing a correction, with investors reevaluating its valuation due to high price-to-earnings and price-to-book ratios.

Becton Dickinson & Co. exceeded expectations in its Q3 2025 earnings call, reporting revenue and earnings growth, a boost in earnings guidance, and a significant increase in stock price.

Becton Dickinson & Co exceeded earnings and revenue expectations in the third quarter of 2025, with a significant surge in revenue and a substantial increase in stock price.

Becton Dickinson & Co, a leading medical technology company, has achieved a diamond-level rating for supply chain resilience and remains committed to innovation, positioning it for future growth and success.

Becton Dickinson & Co.’s stock price is currently at $176.37, with a relatively high valuation and moderate market sentiment, making its financial performance a key area to watch.

Becton Dickinson & Co. has made two groundbreaking announcements, including a revolutionary at-home HPV test and a rapid COVID-19 diagnostic solution, further solidifying its leadership in medical technology.